Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses
Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney...

Related Keywords

United States ,San Diego ,California ,Jay Hagan ,Alan Yu ,Preston Klassen ,Rnas The Company Or Regulus ,University Of Kansas Medical Center ,Exchange Commission ,Regulus Therapeutics Inc ,Nasdaq ,Prnewswire Regulus Therapeutics Inc ,Head Of Research Development Regulus ,Kansas Medical ,Dominant Polycystic Kidney Disease ,Private Securities Litigation Reform Act ,Markets ,